Sign inJoin waitlistJoin the waitlist

Narendranath Epperla

Associate Professor · University of Utah Health

Credentials: · · · ·

History

University of Utah Health
Present

Research

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Blood · 2024 · 139 citations
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Blood · 2021 · 94 citations
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
British Journal of Haematology · 2018 · 92 citations

Reem Karmali
43 papers
TF
Timothy Fenske
30 papers
SB
Stefan Barta
29 papers
Natalie Grover
28 papers
Beth Christian
27 papers
David Bond
26 papers
Jonathon Cohen
26 papers
TV
Timothy Voorhees
26 papers · 7 as a fellow
YS
Yazeed Y Sawalha
26 papers
Pallawi Torka
24 papers
Kami Maddocks
23 papers
Adam Olszewski
22 papers

Grants

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
National Cancer Institute · UM1
PI · $3.4M · Ohio State University
2014–2027

Clinical trials

Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Principal investigator · Not yet recruiting · Phase 1, Phase 2
University of Utah
2026–2031
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Principal investigator · Not yet recruiting · Phase 2
University of Utah
2026–2035
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Principal investigator · Withdrawn · Phase 1
University of Utah
2026–2031
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Principal investigator · Active not recruiting · Phase 2
University of Utah
2025–2027